Synonyms: 18F-AV-1451 | [F-18]T807 | flortaucipir F-18 | LY-3191748 | Tauvid®
flortaucipir (18F) is an approved drug (FDA (2020), EMA (2024))
Compound class:
Synthetic organic
Comment: Flortaucipir (18F) is an investigational PET imaging agent (diagnostic radiopharmaceutical) designed to visualise tau protein (MAPT; P10636) in Alzheimer's disease brains. Compare with the approved agent, florbetapir, used to visualise β-amyloid.
|
|
No information available. |
Summary of Clinical Use ![]() |
In May 2020, the FDA approved flortaucipir F18 as a radioactive diagnostic agent for PET scans of patients being evaluated for Alzheimer's disease. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Binding to Tau protein permits the investigation of Tau pathology in neurodegenerative brain disease by in vivo neuroimaging. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02016560 | Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects | Phase 2/Phase 3 Interventional | Avid Radiopharmaceuticals |